Cardiovascular Risk and MASLD – Integrating Lipid Management with Novel Agents
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on X:
“Understanding MASLD, from molecular pathogenesis to cardiovascular risk.
A concise review for the clinical cardiologist.
MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia. Increased VLDL, small dense LDL, dysfunctional HDL.
The review in ATH journal highlights that.
•Statins are both safe and effective in MASLD, yet underprescribed.
•Ezetimibe and pemafibrate may improve lipid profile and hepatic parameters.
•GLP-1RAs and SGLT2i show dual benefit on liver fat, cardiometabolic risk, and CVD outcomes.
•Emerging agents (resmetirom, lanifibranor) target both hepatic fibrosis and lipid metabolism.
Lipid-lowering therapy remains central in MASLD management, but must be integrated with newer agents for optimal cardio-hepatic protection .”
Read more here.
Stay informed with Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026